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1  | INTRODUC TION
Autosomal recessive spinal muscular atrophy with respiratory dis-
tress type 1 (SMARD1) is a form of spinal muscular atrophy with se-
vere diaphragmatic involvement that causes respiratory distress. This 
condition is due to autosomal recessive mutations in the IGHMBP2 
gene, which is located on chromosome 11q13.2-q13.4.1,2 Mellins, 
considering this mutation a variant of spinal muscular atrophy (SMA) 
5q with respiratory onset, provided the first description of this con-
dition in 1974, and it was not recognized as a separate clinical entity 
until 1996.3,4 The actual prevalence of SMARD1 is unknown, but 
diaphragmatic paralysis is observed in approximately 1% of patients 
with an early onset of the clinical features of spinal muscle atrophy 
and an estimated incidence of 1/100 000.5 The main clinical feature 
is the onset of respiratory distress requiring mechanical ventilation 
between the ages of 6 weeks and 6 months. The clinical symptoms 
rapidly progress in the first years of life, with distal limb muscular 
atrophy extending to proximal regions. The overall prognosis is poor, 
and progressive autonomic nervous system dysfunction also devel-
ops in association with the progressive worsening of motor func-
tions in affected children. In fact, there are no approved treatments 
for SMARD1.6
 
Received: 22 April 2019  |  Revised: 14 September 2019  |  Accepted: 10 November 2019
DOI: 10.1111/jcmm.14874  
R E V I E W
Spinal muscular atrophy with respiratory distress type 1: 
Clinical phenotypes, molecular pathogenesis and therapeutic 
insights
Matteo Saladini1 |   Monica Nizzardo2 |   Alessandra Govoni2  |   Michela Taiana2 |   
Nereo Bresolin1,2 |   Giacomo P. Comi1,3 |   Stefania Corti1,2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2019 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1Dino Ferrari Centre, Neuroscience Section, 
Department of Pathophysiology and 
Transplantation (DEPT), University of Milan, 
Milan, Italy
2Foundation IRCCS Ca' Granda Ospedale 
Maggiore Policlinico, Neurology Unit, Milan, 
Italy
3Foundation IRCCS Ca' Granda Ospedale 
Maggiore Policlinico, Neuromuscular and 
rare diseases unit, Milan, Italy
Correspondence
Stefania Corti, Dino Ferrari Centre, 
Neuroscience Section, Department of 
Pathophysiology and Transplantation 
(DEPT), University of Milan, Foundation 
IRCCS Ca' Granda Ospedale Maggiore 
Policlinico, Neurology Unit, Via Francesco 
Sforza 35, 20122, Milan, Italy.
Email: stefania.corti@unimi.it
Funding information
This work was partially supported by the 
Italian Ministry of Health (MoH) with grants 
to MN, NB, GPC and N. B. Cariplo grant 
to MN is gratefully acknowledged. Grant 
Number:GR-2016-02362377
Abstract
Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is a rare autoso-
mal recessive neuromuscular disorder caused by mutations in the IGHMBP2 gene, 
which encodes immunoglobulin μ-binding protein 2, leading to progressive spinal 
motor neuron degeneration. We review the data available in the literature about 
SMARD1. The vast majority of patients show an onset of typical symptoms in the 
first year of life. The main clinical features are distal muscular atrophy and diaphrag-
matic palsy, for which permanent supportive ventilation is required. No effective 
treatment is available yet, but novel therapeutic approaches, such as gene therapy, 
have shown encouraging results in preclinical settings and thus represent possible 
methods for treating SMARD1. Significant advancements in the understanding of 
both the SMARD1 clinical spectrum and its molecular mechanisms have allowed the 
rapid translation of preclinical therapeutic strategies to human patients to improve 
the poor prognosis of this devastating disease.
K E Y W O R D S
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2  | CLINIC AL FE ATURES
2.1 | Neonatal features
There is no specific neonatal clinical marker of this disease, although 
intrauterine growth retardation and premature birth are very com-
mon.6 The majority of affected children present with nonspecific 
symptoms, such as weak cry, hypotonia, feeding problems, weak 
suckling and recurrent respiratory infections, in the first weeks of 
life.5,7 Congenital foot malformations caused by distal muscle de-
velopment defects and by the deposit of fatty pads in the proximal 
phalanges are also frequently found.8
2.2 | Respiratory distress
Respiratory distress is usually the presenting clinical symptom and 
occurs between 6 weeks and 6 months of age as a consequence of 
the development of neurogenic diaphragmatic palsy. The presenta-
tion of respiratory distress is characterized by inspiratory stridor, 
weak cry, recurrent bronchopneumonia and trouble eating. This 
condition is almost always life-threatening in the absence of medi-
cal intervention; thus, a “pro-life decision” is often required before 
the diagnosis is genetically confirmed.6,8-10 Unlike SMA patients, 
who exhibit a bell-shaped chest and paradoxical respiration as a 
consequence of intercostal muscle palsy, SMARD1 patients have a 
normal-shaped thorax because the defect mainly involves the dia-
phragm.5-8 Chest X-ray, which can show the characteristic eventra-
tion (the abnormal elevation) of the right or, less frequently, both 
hemidiaphragms, which is considered a highly suggestive sign of 
SMARD1, plays a core role in the diagnostic pathway. The confirma-
tion of paralysis can be achieved by performing a chest ultrasound, 
diaphragmatic electromyography or fluoroscopy.5-8
2.3 | Neuromuscular features
The degeneration of the phrenic nerve is accompanied by the pro-
gressive wasting of the distal muscles of the limbs; the lower limbs 
are affected earlier than the upper limbs, and the proximal muscles 
become affected along with the progression of the disease.6,10 The 
natural history of SMARD1 leads to complete paralysis of the four 
limbs, with an absence of deep tendon reflexes usually after the first 
year of life and the development of rachis malformations, such as 
kyphoscoliosis. The clinical features seem to progress most rapidly 
in the first two years of life, followed by a stabilization of the pat-
tern and sometimes a mild improvement of some functions, such as 
respiratory activity and muscle strength, most likely due to the re-
generation of some muscle fibres.6,8,10
Regarding neurological assessment, motor development mile-
stones and communication skills, in particular those specified in the 
semiquantitative scoring system by Eckart et al,10 have been pro-
posed as outcome measures Table 1. The authors proposed applying 
this score monthly in the first year of life and then yearly during 
follow-up.
2.4 | Central and autonomic nervous system 
abnormalities
Cranial nerves are frequently involved in the natural course of 
SMARD1, although not as a presenting feature; mimicking patholo-
gies, such as muscle weakness and tongue fasciculations, have been 
reported as signs of hypoglossal nerve paralysis, while the oculomo-
tor nerves are usually spared. Epileptic seizures have also been re-
ported, but these disorders do not seem to be aetiologically related 
to the disease.8 Autonomic nervous system involvement is common 
in SMARD1 patients and manifests mainly as bladder incontinence, 
urinary retention with the need for catheterization, excessive sweat-
ing, constipation and cardiac arrhythmia.6,8 In some cases, autonomic 
dysfunction can be the prominent feature of the clinical course, such 
as in the case of a Japanese girl affected with genetically confirmed 
SMARD1 who presented with catastrophic autonomic crisis with 
cardiac collapse, as reported by Nomura and colleagues.11
3  | DIAGNOSIS
SMARD1 patients typically present with phrenic nerve palsy be-
tween the ages of six weeks and six months, and motor neuron de-
generation primarily affects the distal muscles, particularly those of 
the lower extremities.6 According to a cohort study enrolling 141 pa-
tients by Guenther and colleagues, the combination of these features 
is present in 86% of patients with IGHMBP2 mutations. Moreover, 
the onset of respiratory distress between six weeks to six months 
of age combined with preterm birth or right diaphragm eventration 
seems to predict the disease with a sensitivity of 98% and a specific-
ity of 92%.12 Conversely, the congenital onset of respiratory distress 
is not typical in SMARD1 and is consistent with other more com-
mon diagnoses, the most common of which are SMA1, congenital 
TA B L E  1   Semiquantitative original scoring system, from Eckart 
and colleagues
Eckart's semiquantitative scoring system for SMARD1 Y/N
1 Onset of mechanical ventilation  
2 Onset of muscle weakness  
3 Remaining antigravity movements in arms  
4 Remaining antigravity movements in legs  
5 Sitting without support  
6 Holding the head upright while in sitting position  
7 Reduction in facial expression  
8 Ability to speak  
9 Freedom from cerebral seizures  
10 Dysfunction of the autonomic nervous system  
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myotonic dystrophy type 1 (cDM1), early-onset myopathy, areflexia, 
respiratory distress and dysphagia (EMARDD), and congenital myas-
thenia gravis.8,10,13,14 The current practice is to follow the diagnostic 
criteria for SMARD1 provided by Pitt and colleagues in 2003, which 
are reported in Table 2.
In a recent retrospective analysis of 22 cases, the authors con-
firmed the predictive effects of Pitt's criteria for the diagnosis of 
SMARD1, but at least 4 of the patients had normal chest X-rays 
at the onset of respiratory distress. Based on this evidence, these 
authors hypothesized that genetic tests for IGHMBP2 could be 
performed even before the onset of diaphragm eventration. This 
hypothesis is justified by the observation that 28.6% of the cases 
involved intrauterine growth restriction (IUGR) and distal defor-
mities at birth and suggests that clinicians should be alerted in 
each case of a premature newborn with symmetrical IUGR under 
the 10th percentile and respiratory warning signs (weak cry, stri-
dor and feeding difficulties), even without positive chest X-ray 
findings.16
4  | NATUR AL COURSE AND PROGNOSIS
SMARD1 is a chronic, congenital and untreatable disease, and much 
progress is still needed to improve the outcomes and quality of the 
lives of affected patients. In 2012, Eckart and colleagues reported 
a broad analysis of the natural course of life in 11 SMARD1 cases, 
in which these authors observed that the loss of independent 
breathing and the onset of muscle weakness took place between 
2 and 9 months of age, prompting an immediate pro-life decision. 
By 9 months, all of the patients needed mechanical ventilation 
to survive, and only one of the patients, who was able to regain 
the ability to breathe independently through the use of accessory 
muscles for 12 hours per day, could be weaned from mechanical 
ventilation during the observation period, which was on average 
7.8 years. None of the patients were able to reach and maintain 
a standing position or walk and thus needed wheelchair mobiliza-
tion. Autonomic nervous system failure was present in all of the 
patients, the most recent of which developed this condition beyond 
the age of 9 years. Seven out of the 11 patients underwent echo-
cardiographic screening, with no evidence of any structural cardiac 
abnormality being found.
At the end of the observational period, 7 out of the 11 children 
exhibited normal facial expressions, four patients could sit and hold 
their heads, six were able to speak through a speech cannula or a leak 
in their tracheal cannula, and five patients remained seizure-free. All 
of these patients, with the exception of one, lived at home and could 
have normal social interactions with other children.
This study demonstrated marked differences in the severity 
and rate of progression of symptoms in patients with improved se-
verity scores between 1 and 3 years of age. Moreover, the authors 
observed that an overall higher score at the age of 3 years was usu-
ally associated with a slower progression of the disease and milder 
symptoms.
The overall survival rate of SMARD1 without artificial ventila-
tion, with a mean age of death of 9 months, is very poor.17 Evidence 
suggests that there are three different forms of SMARD1 that vary 
based on the age of onset: an early-onset form, which usually ap-
pears before three months of age and is very severe, a classical 
onset form; and a very rare late-onset form, which is characterized 
by milder symptoms and a slower progression compared with that 
of the classical onset form and affects patients usually after the 
age of 12 months.17 As of now, the oldest affected patient to be 
described was a 21-year-old girl. After having achieved the abil-
ity to crawl and stand with support, she was clinically diagnosed 
at the age of 16 months after presenting with mild right hemid-
iaphragm eventration upon chest X-ray and a clinical picture of 
cough, wheeze and signs of respiratory distress. Successive analy-
ses confirmed the diagnosis of a late-onset form of SMARD1. This 
patient uses a ventilator only at night, and her cognitive skills are 
unaffected.18
The death of the great majority of patients is caused by the de-
velopment of respiratory failure or by complications related to me-
chanical ventilation, such as sepsis or pneumonia. The average life 
expectancy is very difficult to estimate because it depends on the 
severity of respiratory involvement, provided treatments and sus-
ceptibility to ventilator-associated complications.10
TA B L E  2   The diagnostic criteria for SMARD1, which may permit its effective distinction from other similar conditions15
Clinical criteria Histopathological criteria EMG criteria
Low birthweight below the 3rd centile Reduction of myelinated fibre size in sural nerve biopsies Evidence of acute or chronic distal 
denervation
Onset of symptoms within the first 3 months Minimal evidence of ongoing myelinated fibre degenera-
tion in biopsies taken up to 3 ± 4 months
Evidence of severe slowing (<70% 
of lower limit of normality in 
one or more nerves (motor or 
sensory))
Diaphragmatic weakness either unilaterally or 
bilaterally
No evidence of regeneration or of demyelination that 
might account for the change in fibre size.
 
Ventilator dependence within less than one 
month of onset with an inability to wean
  
Absence of other dysmorphology or other 
conditions
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5  | PATHOGENESIS
SMARD1 is caused by autosomal recessive mutations in IGHMBP2 
on chromosome 11q13.2-q13.4.1,2 Human IGHMBP2 is composed of 
15 exons and encodes immunoglobulin µ-binding protein 2, a protein 
that comprises 993 amino acids (109 149 Da) and whose function is 
not still understood. The gene product is an ATPase/helicase of the 
SF1 superfamily that is ubiquitously expressed, although this protein 
is expressed mainly in the cytoplasm, where it associates with ribo-
somes.19 The IGHMBP2 gene harbours four domains: an ATPase do-
main, a single-stranded nucleic acid-binding R3H domain, a DEXDc 
domain and an AN1-type zinc finger motif. Biochemical characteriza-
tion has determined that IGHMBP2 is an ATP-dependent 5’→3’ DNA/
RNA helicase. Most SMARD1-causing missense mutations have been 
found in the helicase domain, which contains two recA-like subdo-
mains and at least seven highly conserved motifs of amino acids, sug-
gesting that this domain may play a central role in the pathogenesis of 
the disease.9,20 Further investigations have revealed that the synergy 
of the helicase domain with the R3H domain leads to an enhanced 
RNA binding affinity, thus potentiating its ATPase activity.21
The IGHMBP2 protein comprises a DNA/RNA helicase domain, an 
R3H domain, a zinc finger domain, a DEXDc domain and an AN1-type 
zinc finger motif. Based on sequence homology, this protein has been 
classified as part of the UPF1-like group of helicase superfamily 1 (SF1). 
The full extent of the function of the IGHMBP2 protein is not yet known, 
although this protein may take part in several different cellular functions, 
such as pre-mRNA processing, immunoglobulin class switching, and the 
regulation of DNA replication and the interaction with the TATA-binding 
protein. Furthermore, IGHMBP2 acts as an ATP-dependent helicase and 
may play a role in ribosomal translation and biogenesis.2,21
The fact that the great majority of known IGHMBP2 mutations are 
located in the helicase and R3H domains has led the authors to believe 
that these domains are essential to the function of the protein and has 
sparked interest in correlating the level of ATPase activity to the severity 
of the clinical phenotype. In Guenther et al9 was the first group to study 
the protein expression levels in EBV-immortalized lymphoblastoid cell 
lines (LCLs) from SMARD1 patients and their parents. These authors 
found that patients with a milder juvenile form of SMARD1 had higher 
levels of protein expression than those of severe SMARD1-affected pa-
tients and that their parents expressed proteins at a level that was 75% 
of that exhibited by healthy controls. Moreover, these authors observed 
that the mRNA levels were not correlated with the amount of functional 
protein and thus concluded that SMARD1 pathogenesis may be related 
to reduced translation or protein degradation rather than diminished 
mRNA levels (Guenther et al9). Further evidence is required to better 
confirm the existence of this correlation because it may be very import-
ant in the development of therapeutic strategies for SMARD1.
6  |  IG H M B P2  MUTATION IN CHARCOT-
MARIE-TOOTH DISE A SE
Charcot-Marie-Tooth disease (CMT) is a spectrum of multiple he-
reditary syndromes causing the progressive length-dependent 
degeneration of peripheral sensory and/or motor fibres. CMT has 
an estimated prevalence of 1:2500, and its aetiology is related 
to more than 80 different genes.22 The diverse phenotypic and 
electrophysiological symptoms lead to the classification of CMT 
by type (type 1 and type 2).22,23 In 2012, the Cottenie group dis-
covered an IGHMBP2 mutation in two consanguineous English 
patients affected by CMT type 2S disease (CMT2S) through a com-
bination of genome sequencing and linkage analysis. Pathological 
studies showed some differences between the features of these 
patients and the typical CMT2 pattern observed in cases in-
volving mutations in MFN2. CMT2 cases involving mutations in 
IGHMBP2 tend to have a milder involvement of large myelinated 
fibres, which is almost absent in CMT2 cases involving mutations 
in MFN2, which show no involvement of small fibres. Moreover, 
ultrastructural analysis showed few actively degenerating axons, 
which are very rare in patients with MFN2 mutations.24 In re-
cent years, many other similar cases have been described, and to 
date, 21 recessive IGHMBP2 variants have been associated with a 
CMT2S phenotype.25,26
The observation that CMT2S and SMARD1 are caused by dif-
ferent mutations in the same gene led the authors to investigate 
the cause of the differences in clinical phenotype. Mutations in 
SMARD1 are predominately missense and located in the helicase 
domain, while in CMT2, the mutations were mainly a combination 
of a nonsense mutation in the 5′ region of the gene with trun-
cating frameshift, missense or homozygous frameshift mutations 
in the last exon. This different combination of mutations in the 
two diseases leads to a different amount of residual protein. In 
fact, the quantification of protein levels in fibroblasts and lym-
phoblastoid cell lines demonstrated that CMT2S patients have 
significantly higher IGHMBP2 protein levels than SMARD1 pa-
tients, although a defective truncated protein was found in many 
cases. Furthermore, the mRNA levels were normal or higher 
than normal in both cell lines, suggesting that posttranslational 
degradation mechanisms may be responsible for the absence of 
the IGHMBP2 protein and a correlation between the phenotype 
and the quantity of residual protein has therefore been hypoth-
esized.24 Moreover, the function of IGHMBP2 is similar to that 
of GARS, AARS, HSPB1 and HSPB8, which have all been associ-
ated with both CMT and distal hereditary motor neuronopathy 
(dHMN) phenotypes. This evidence suggests that dysfunctions 
in RNA processing mechanisms may selectively affect periph-
eral nerves with a severity that varies according to the degree of 
dysfunction.26
7  | IN VITRO AND IN VIVO DISE A SE 
MODEL S
The development of in vitro and in vivo models for SMARD1 has per-
mitted great advances in the comprehension of pathogenetic mech-
anisms and in therapeutic studies. Two main models of SMARD1 and 
neuromuscular diseases in general have been developed: the stem 
cell model and the murine model.
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7.1 | The stem cell model
The first option for reproducing neuromuscular diseases in the labo-
ratory originates from the isolation of human embryonic stem cells 
(hESCs) from the inner cell mass of the blastocyst, which was first 
reported in 1998.27 In 2006, a study by Takahashi and Yamanaka 
demonstrated the ability to reprogramme fibroblasts from adult 
mice into induced pluripotent stem cells (iPSCs), which represented 
an important advancement and opened the path for the use of stem 
cells in disease models and as a therapeutic tool. The factors Oct3/4, 
Sox2, c-Myc and Klf4 act together to overwhelm skin gene expres-
sion in fibroblasts and can activate genes encoding hESC proteins, 
thus inducing the reprogramming of somatic cells into iPSCs.28 iPSCs 
offer great advantages compared to hESCs because these cells can 
be obtained from virtually any patient through a small skin biopsy 
sample or blood sample with no need to fertilize an embryo, thus re-
ducing ethical issues, costs and the complexity of the procedure.29,30
Our group provided one of the first descriptions of the gen-
eration of IGHMBP2-mutated iPSCs from SMARD1 patients for 
in vitro studies of SMARD1.31,32 As observed in SMA, SMARD1 
iPSC-derived motor neurons exhibit reduced survival and axonal 
length in culture, thus recapitulating the key features of human 
disease.
The limitations of the cell model are represented mainly by the 
inability to study the in vivo events that influence motor neuron 
development and degeneration, which are key aspects of SMARD1 
pathogenesis.
7.2 | The murine model
The Cox group provided the first identification of a spontaneous 
ighmbp2 mutation in mice in 1998. So-called neuromuscular degen-
eration (nmd) mice develop a disease that is similar to the human 
disease, with motor neuron degeneration, skeletal muscle atrophy 
and limb paralysis. Paralysis usually begins in the hindlimbs between 
the ages of 2 and 3 weeks, and then, the disease spreads to the trunk 
and the forelimbs. The affected mice often experience a slowdown 
in the progression of symptoms after that period, and most of these 
animals survive until the age of 14 weeks. The original phenotype 
of the mice was more severe, and the mice rarely survived beyond 
4 weeks.33 The main difference between murine disease and human 
SMARD1 is that respiratory failure occurs at later stages in mice and 
is not usually the cause of death, which results apparently from di-
lated cardiomyopathy.16,34
Current evidence suggests that motor neuron loss begins before 
the onset of clinical symptoms and that it does not affect myelin 
sheets in the early stages of the disease.34 The gastrocnemius has 
been found to be the most vulnerable muscle, while clinical evi-
dence suggests that neural muscular junction (NMJ) denervation 
minimally affects the diaphragm, confirming the key difference in 
human SMARD1 patients. Furthermore, the fragmentation of the 
end motor plate has been detected in all analysed muscles and has 
been determined to be independent of their susceptibility to dener-
vation, suggesting a role for the ighmbp2 protein in preventing this 
fragmentation.16
8  | THER APEUTIC PERSPEC TIVES
Unfortunately, there is no currently available treatment for 
SMARD1. The collaboration between physicians and caregivers is 
thus fundamental to appropriately manage the critical condition 
of each patient, which can be a burden for all of the people liv-
ing around the patient. The first important decision is whether to 
intubate and mechanically ventilate the child. SMARD1-affected 
children have very little independence in everyday activities and 
often experience difficulties in feeding due to neck muscle weak-
ness and autonomic dysfunction; thus, these children require 
continuous physical therapy to delay the onset of orthopaedic 
problems of the dorsal spine.7,10 Discharge to home care is usually 
possible when the vital signs become stable and must always be 
the preferred option to prevent the onset of the typical complica-
tions of hospitalization, such as nosocomial infections.10 In recent 
years, many studies on the development of therapies for SMARD1 
have been conducted in preclinical settings Figure 1.
8.1 | Pharmacological studies
From a pharmacological point of view, there has been much atten-
tion paid to determining the therapeutic effect of neurotrophins in 
neurodegenerative diseases, particularly in those that affect motor 
neurons.35,36
The Ruiz group tested the benefits of using an agonistic mono-
clonal antibody against trkC receptors (Mab2256) in nmd mice. 
Tyrosine kinase receptor phosphorylation plays a central role in the 
neuronal response to neurotrophic factors, such as brain-derived 
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF) and 
neurotrophin 3/4/5 (NT 3/4/5).37 However, the antibody failed to 
improve the lifespan of nmd mice, despite the transient amelioration 
of muscle strength, as demonstrated by EMG studies. Two possi-
ble explanations for the failure of this experiment are that the high 
haematic level of Mab2256 deregulated the trkC receptor and that 
the antibody did not have the required affinity for effect on the 
receptor.38
Another group headed by Krieger identified low haematic levels 
of IGF1 in nmd mice; thus, these authors investigated whether the 
lack of insulin-like growth factor 1 (IGF1) is involved in motor neuron 
degeneration in SMARD1. The authors treated the mice with poly-
ethylene glycol-coupled IGF1 (PEG-IGF1) and achieved an increase 
in plasma IGF1 levels, which was associated with the amelioration 
of neuromuscular deficits, an improvement in body weight and 
length, and a reduction in action potential amplitude in EMG stud-
ies compared to those of the untreated controls. Moreover, upon 
neuropathological examination, the nerve and muscle fibres were 
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F I G U R E  1   Illustrative image of 
preclinical therapeutic approaches 
for SMARD1. A, Stem cell therapy for 
SMARD1. Human induced pluripotent 
stem cells (iPSCs) can be generated 
from adult fibroblasts through exposure 
to the reprogramming factors OCT4, 
SOX2, NANOG, LIN28, c-Myc and KLF4. 
SMARD1 spinal motor neurons (MNs) can 
be obtained through the differentiation 
of iPSCs to reproduce a disease-specific 
model. The MN defects can then be 
corrected, and the healthy neural stem 
cells (NSCs) can be transplanted into an 
nmd mouse to obtain an amelioration of 
behavioural deficits in the animal. B, Gene 
therapy approach. The defective gene is 
replaced by the injection of recombinant 
adeno-associated virus 9 (rAAV9) vectors 
to rescue the phenotype of the animal
     |  7SALADINI et AL.
larger. Despite these optimistic results, no improvement in motor 
neuron survival was achieved, in accordance with Ruiz's results. The 
author's hypothesis was that the systemic PEG-IGF1 concentration 
was not high enough to pass through the blood-brain barrier, thus 
limiting the efficacy of this treatment.39
In conclusion, studies on neurotrophic factors have revealed ev-
idence to justify future experiments to clarify whether therapeutic 
effects can be achieved using these substances.
8.2 | Stem cells
Thus far, the use of stem cells as a therapeutic tool for neuromuscu-
lar diseases has been widely investigated because these cells permit 
the replacement of degenerating motor neurons and produce cy-
tokines and other neuroprotective factors that can help to prevent 
motor neuron loss.40,41
Our group conducted various studies aiming to develop stem cell 
therapies for SMARD1. In the first study, the authors observed that 
neural stem cells transplanted intrathecally into nmd mice could dif-
ferentiate into three principal lineages, suggesting that the cellular 
environment is fundamental for stem cell differentiation. Moreover, 
the injected cells demonstrated the ability to differentiate into 
motor neurons, migrate and send their axons into the white matter 
and anterior horn and provided evidence of a remarkable ameliora-
tion of the neurogenic atrophy phenotype without preventing the 
premature death of the nmd mice.42
In a second study, we transplanted cells that had been previ-
ously differentiated into motor neurons in vitro into nmd mice via 
local delivery to determine whether the clinical phenotype could 
be improved. We observed that the treated nmd mice had higher 
body weights and lengths and better motility, as measured by the 
rotarod test. Moreover, the assessment of GFP in the engrafted 
neurons permitted us to determine how donor cells survive in the 
host; we found that the neurons exhibited good extension into the 
ventral roots and the corresponding white matter. Based on the 
results of this experiment, we concluded that motor neuron trans-
plantation can improve clinical and neuropathological conditions in 
nmd mice.43
In a third study in 2014, we demonstrated the correlation be-
tween iPSC-derived neural stem cell transplantation and improve-
ments in clinical phenotypes and lifespan in nmd mice. We also 
observed that the number of motor neurons was significantly higher 
in the treated nmd mice than in the untreated controls. Moreover, 
we treated SMARD1 iPSC-derived motor neurons and observed an 
amelioration of the growth and size of these cells. The hypothesis, 
based on the observed data, is that this improvement may be due 
to the production of neurotrophins (GDNF, BDNF, NT-3 and TGF-α) 
and the inhibition of HGK and GSK-3 kinases.31
In conclusion, stem cells represent a valid and encouraging ther-
apeutic perspective not only for SMARD1 but also for many other 
neurodegenerative diseases. The next steps that will allow the pro-
gression of this field involve other in vitro studies, followed by the 
in vivo testing of human stem cells to better clarify the efficacy of 
this therapeutic tool alone and in combination with other strategies.
8.3 | Gene therapy
Gene therapy is the third possible approach to SMARD1 treatment, 
and its great advantage is that this therapy may have the potential 
to replace the deficient gene and restore a significant amount of 
protein. Recently, many gene therapy studies have been conducted 
in the context of neuromuscular disorders, and very encouraging 
results have been achieved in the treatment of SMA and in human 
clinical trials.44,45 Despite these results, few studies have been per-
formed with the same therapeutic approach in SMARD1 patients. 
Our group has made great efforts to test the efficacy of a gene 
therapy approach in an animal model of SMARD1.32 Our first study 
in 2015 showed that compared to untreated nmd mice, treated nmd 
mice (5 × 1011 viral particles administered intravenously at P1) ex-
hibited significantly improved phenotypes in terms of lifespan (450% 
higher), motor function, the myofibre size of skeletal and cardiac 
muscles and anterior horn fibre myelination. Moreover, we gener-
ated in vitro spinal motor neurons from SMARD1 patients to verify 
the efficacy of this treatment in the best available model of human 
disease, and the obtained results were also encouraging, compared 
to untreated cells, the motor neurons treated with the IGHMBP2 
vector exhibited increased survival, neurite length and IGHMBP2 
expression.
The other important issue regarding gene therapy is its clinical 
translation, as three possible routes of adeno-associated virus (AAV) 
vector administration have been described (intramuscular (IM), intra-
venous (IV) and intracerebroventricular (ICV).46 Although IV injec-
tion is a minimally invasive intervention and enables the viral vector 
to reach tissues other than those of the central nervous system, this 
route of administration requires more virus with an augmented rate 
of immunogenicity.
In two recent studies, Shababi and colleagues tested the ICV 
route (Shababi et al, 47) and compared this route with the IV route.48 
In the first paper, these authors treated mice by ICV injection with 
2 doses of virus (1.25 × 1011 or 2.5 × 1011 viral genomes, with the 
higher dose in a double volume of injection). The lower dose was 
associated with a significant improvement in phenotype and sur-
vival, while the higher dose was correlated with the development 
of hydrocephalus in both heterozygous and homozygous nmd mice 
within 1-1.5 months of injection. The reason for this side effect is 
not completely defined, but it appears that both homozygous and 
heterozygous mice were affected, thus, it seems that the cause is 
related to the specific mouse genetic background rather than to the 
disease per se.
Moreover, in the second study, Shababi et al compared pheno-
typic amelioration in nmd mice treated with the IV and ICV admin-
istration of rAAV vectors targeting IGHMBP2 (both at the same low 
dose of 1.25 × 1011). Both treated groups showed a similar extension 
of lifespan (more than 200 days), weight gain and improvement in 
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the histological features of cardiomyocytes and in cardiac fibrosis, 
with a significant delay in the onset of dilated cardiomyopathy com-
pared with that of the untreated controls. However, the ICV-treated 
mice gained more weight, and these mice showed significantly bet-
ter rescue of hindlimb motor function, with a significant reduction in 
gastrocnemius contracture and a great improvement in the rotarod 
test performance compared to that of both the untreated controls 
and the IV-treated mice. The authors concluded that the two meth-
ods of administration can be considered equally effective in the 
rescue of the disease phenotype of nmd mice due to the equivalent 
lifespan prolongation and cardiac improvement. ICV injection was 
instead correlated with a better improvement in hindlimb function.48 
However, although the ICV and IV doses were the same, the quan-
tity of lentiviral particles received by the CNS may have been higher 
after ICV delivery compared to IV delivery as ICV injections are de-
livered locally while IV injections are delivered systemically.
In conclusion, gene therapy seems to show encouraging results 
in laboratory and in vivo tests and thus requires great effort to reach 
the knowledge necessary to treat SMARD1.
9  | DISCUSSION
Due to the great achievements provided by preclinical research, the 
field of neuromuscular diseases has quickly evolved in recent years, 
and some devastating diseases, such as SMA,44,45 may finally be re-
moved from the list of untreatable diseases. Unfortunately, SMARD1 
remains an unsolved burden, probably due to its lower incidence and 
its complex and poorly understood pathogenetic mechanisms.
The main clinical features of this disease include neonatal onset 
(within the year of life), diaphragmatic paralysis and the wasting 
of distal limb muscles, which leads affected individuals to be com-
pletely dependent on ventilatory support and the daily supportive 
care of parents or caregivers.6,8-10
The prognosis of affected patients is currently very poor,10,17 but 
the advances made in the treatment of similar diseases have made it 
possible to study the therapeutic approaches for SMARD1. The ben-
efits obtained by the in vitro use of neurotrophic factors and phar-
macological agents are not encouraging,38,39 but better results have 
been obtained with the injection of rAAV in nmd mice.32,48
The pathogenetic mechanisms underlying this disease are com-
plex and not yet completely deciphered; in fact, mutations in the same 
IGHMBP2 gene can determine very serious (SMARD1) or mild pheno-
types (CMT). Moreover, SMARD1 itself demonstrated substantial vari-
ability in terms of age of presentation, severity of the symptoms and 
survival. The role of the protein in the CNS and in other systems and 
how the different mutations impact the pathogenesis need to be bet-
ter characterized because the behaviour of the wild-type and mutated 
proteins affects the strategy of application and the rate of success of 
the potential therapy. For example, the type of administration adopted 
is crucial; in fact, although ICV administration would make it possible 
to reach the central nervous system directly, systemic administration 
would have the advantage of reaching other tissues that are known 
to be affected by the pathogenesis. Nevertheless, the published data 
and the results obtained also by our group show that gene therapy 
represents a real potential for the treatment of SMARD1. To verify the 
amplitude of this potential, further studies will be required, aiming to 
increase the number of analysed cases, thus permitting a wider statis-
tical analysis of the correlation between genotype, IGHMBP2 mRNA 
and protein levels in animal models and human iPSCs, and the clini-
cal phenotypes observed. Future advances in the knowledge of the 
pathogenetic mechanisms of this disease and in gene therapy adminis-
tration will also permit the development of new experimental trials to 
better clarify its applicability in human SMARD1 patients.
There are still many unsolved questions, such as the best route 
of administration, the immunogenicity of these therapies in humans, 
the possible side effects and the long-term efficacy.
For the transition into the clinic, it is necessary to proceed with 
the validation of the method in the preclinical phase and invest in 
this research pathology, which, although rare, shares pathogenetic 
aspects with SMA and therefore also the susceptibility of treatment 
for SMARD1 patients.
The SMARD1 therefore represents an excellent candidate for 
the application of this innovative method, which has been demon-
strated to be increasingly promising in the treatment of both neuro-
muscular and other diseases.
In conclusion, treatments for SMARD1 are not currently avail-
able, but recent preclinical therapeutic advances have laid the foun-
dation for future solutions to this health issue, and the combination 
of various therapeutic possibilities that have been studied may lead 
to an effective therapy for SMARD1 patients.
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